Alx Oncology Holdings Inc ALXO

$1.24 +0.02 (1.64%)

Valuation

Market cap
163,167,000
Revenue TTM
$0
Net income TTM
$-101,700,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.07

Trading

Volume
127,976
Avg volume
1,240,552
Day's range
$1.20 – $1.26
Shares out
138,277,000
Stochastic %K
63%
Beta
0.47
Analysts
Strong Sell
Price target
$4.60

Price

Company profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Ev...

Show more

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 466 7125
Website
https://www.alxoncology.com
Address
323 Allerton Avenue, South San Francisco, United States

Latest news

Stocktwits

Dieseld28 Oct 16, 3:52 PM
$XLAB $ALXO
0 replies
StarLord13 Oct 14, 9:21 PM
$ALXO Wow, looks like it’s heading down to 40 cents again. Glad I unloaded my shares in the $2.20’s.
0 replies
migueljonesbeach Oct 14, 4:18 PM
$ALXO $153.4 million - Cash, cash equivalents, and investments. 10 million in debt.
0 replies
topstockalerts Oct 14, 12:33 AM
After Hours Top Gainers PT2 $ZTG $TCRT $AMTD $ALXO $TWG
0 replies
WS86 Oct 13, 8:33 PM
$ALXO Why the recent selloff?? A little early for tax-loss season.
1 replies
maplelakeduckslayer Oct 13, 8:15 PM
$ALXO ya, began adding into the close lmfao
0 replies
History101 Oct 13, 6:02 PM
$ALXO 1,230 watching 10/13/2026
0 replies
prismmarketview Sep 28, 4:28 PM
PRISM Mid-Day Movers: MedTech and EV are Today’s Leaders. Accuray Incorporated (NASDAQ: $ARAY ) shares were up 52.53% at $0.3281 around midday Monday, a gain of $0.113 from Friday’s $0.2151 close. Kandi Technologies Group Inc. (NASDAQ: $KNDI ) shares were up 32.35% at $0.7782 around midday Monday, a gain of $0.1902 from Friday’s $0.5880 close. Other Notable Movers: Magnachip Semiconductor Corp. ($MX.X) up 16% ALX Oncology ($ALXO)up 8% Safe Harbor Financial ($SHFS ) down -31% Stock prices and percentage changes are as of 12:15 p.m. ET on September 28, 2026, and are subject to change. https://prismmarketview.com/prism-mid-day-movers-medtech-and-ev-are-todays-leaders/
0 replies